Literature DB >> 10907940

Tamoxifen for early breast cancer: better late than never.

R Gray, C Davies, P Perry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10907940     DOI： 10.1023/a:1008323116265

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer.

Authors:  Yoshimasa Kosaka; Naoko Minatani; Yoko Tanaka; Akiko Shida; Mariko Kikuchi; Hiroshi Nishimiya; Mina Waraya; Hiroshi Katoh; Takeo Sato; Norihiko Sengoku; Hirokazu Tanino; Keishi Yamashita; Masahiko Watanabe
Journal:  Mol Clin Oncol       Date:  2018-09-13

2.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Authors:  Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.